Invex Therapeutics Ltd
ASX:IXC

Watchlist Manager
Invex Therapeutics Ltd Logo
Invex Therapeutics Ltd
ASX:IXC
Watchlist
Price: 0.115 AUD Market Closed
Market Cap: AU$8.6m

Net Margin

-103.3%
Current
Improving
by 271%
vs 3-y average of -374.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-103.3%
=
Net Income
AU$-476.9k
/
Revenue
AU$461.5k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-103.3%
=
Net Income
AU$-476.9k
/
Revenue
AU$461.5k

Peer Comparison

Country Company Market Cap Net
Margin
AU
Invex Therapeutics Ltd
ASX:IXC
8.6m AUD
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
216.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

In line with most companies in Australia
Percentile
42nd
Based on 4 004 companies
42nd percentile
-103.3%
Low
-16 177 900% — -544.7%
Typical Range
-544.7% — 3.1%
High
3.1% — 3 174 540%
Distribution Statistics
Australia
Min -16 177 900%
30th Percentile -544.7%
Median -27.7%
70th Percentile 3.1%
Max 3 174 540%

Invex Therapeutics Ltd
Glance View

Market Cap
8.6m AUD
Industry
Pharmaceuticals

Invex Therapeutics Ltd. is a biopharmaceutical company, which engages in the research and development of treatment for neurological conditions resulting from raised intracranial pressure. The company is headquartered in Subiaco, Western Australia. The company went IPO on 2019-07-05. The firm is focused on the development and commercialisation of Presendin (Exenatide) for neurological conditions relating to raised intracranial pressure. The firm received written responses from the United States Food and Drug Administration (FDA) Division of Neurology relating to its proposed Phase III clinical trial design for Presendin in Idiopathic Intracranial Hypertension (IIH). Exenatide is a glucagon-like peptide-1 receptor agonist approved for the treatment of type II diabetes. The firm focuses on reformulating Exenatide to deliver it in a way that enables exploitation of its unknown ability to reduce cerebral spinal fluid secretion in the choroid plexus of the brain. The firm intends to progress expediently to clinical evaluation and undertake the registration of different formulations of Exenatide optimized to treat different neurological conditions.

IXC Intrinsic Value
0.049 AUD
Overvaluation 57%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-103.3%
=
Net Income
AU$-476.9k
/
Revenue
AU$461.5k
What is Invex Therapeutics Ltd's current Net Margin?

The current Net Margin for Invex Therapeutics Ltd is -103.3%, which is above its 3-year median of -374.4%.

How has Net Margin changed over time?

Over the last 3 years, Invex Therapeutics Ltd’s Net Margin has increased from -1 508.2% to -103.3%. During this period, it reached a low of -1 508.2% on May 30, 2022 and a high of 7.9% on Dec 31, 2024.

Back to Top